Dr. Geoffrey Paul Nase - G.P. Nase Online Medical Article

Interesting. I see that Medical Schools are now selling their top medical publications online. I see that Dr. Nase has 17 major medical publications online for sale fro his studies at Indiana University School of Medicine and West Virginia University School of Medicine. They are awfully expensive though for around $50. I think most of this money goes back to the Medical School though???

There are nearly 20 medical studies for sale from his research at Indiana University School of Medicine where he collaborated with Eli Lilly Pharmaceuticals to help develop one of the first prophylactic type II Antidiabetic Drugs (If you actually purchase it the article is a G-Protein Receptor Couple Inibitor Beta II Phosphokinase K Inhibitor that the has passed clinical testing and will soon be an actual prescription).

Dr. Nase published this in The Clinical Journal of Experimental Pharmacology and Physiology. Great job Geoffrey! $50!!!! I hope you get some of the proceeds. It takes a while to download so be patient, but you can see the Eli Lilly (LY) drug produced from their experiements:

Dr. Geoffrey Paul Nase Medical Article on Type II Diabetes Medication

Tons of medical mumbo jumbo but it is interesting how Dr. Nase and Dr. Bohlen took their studies from theory to the lab... to animals (has to be done).... to humans.... to the first drug to prophylactically treat Type II Diabetes!!! Congrats. You'll also see that the study was solely supported by a Post-Doctoral American Heart Association Fellowship awarded to Dr. Nase and co-sponsored by Eli Lilly Pharmaceuticals. Good stuff.

Abstract:

SUMMARY


1. Hyperglycaemia in the vast majority of humans with diabetes mellitus is the end result of profound insulin resistance secondary to obesity. For patients in treatment, hyperglycaemia is usually not sustained but, rather, occurs intermittently. In in vivo studies of the rat intestinal microcirculation, endothelial impairment occurs within 30 min atD-glucose concentrations ≥ 300 mg/dL. Endothelial-dependent dilation to acetylcholine and constriction to noradrenaline is impaired. Vasodilation to exogenous nitric oxide (NO) remains normal.


2. When initiated before hyperglycaemia, suppression of oxygen radicals by both scavenging and pretreatment with cyclo-oxygenase blockade to prevent oxygen radical formation minimized endothelial impairments during hyperglycaemia. Neither treatment was effective in restoring endothelial function once it was damaged by hyperglycaemia.


3. A mechanism that may initiate the arachidonic acid- oxygen radical process is activation of specific isoforms of protein kinase C (PKC). De novo formation of diacylglycerol during hyperglycaemia activates PKC. Blockade of the βII PKC isoform with LY-333531 prior to hyperglycaemia protected NO formation within the arteriolar wall, as judged with NO-sensitive microelectrodes. Furthermore, once suppression of endothelial dilation was present in untreated animals, PKC blockade could substantially restore endothelial-dependent dilation.


4. These results indicate that acute hyperglycaemia is far from benign and, in the rat, causes rapid endothelial impairment. Both oxygen radical scavenging and cyclo-oxygenase blockade prior to bouts of hyperglycaemia minimize endothelial impairment with limited side effects. Blockade of specific PKC isozymes protects endothelial function both as a pre- or post-treatment during moderately severe hyperglycaemia.

Keywords: diabetes; hyperglycaemia; nitric oxide
Document Type: Research article
DOI: 10.1046/j.1440-1681.2002.03617.x
Affiliations: 1: Department of Cellular and Integrative Physiology, Indiana University Medical School, Indianapolis, Indiana, USA


Michael

Seriously... how cool is that?

Dr. Nase was the primary scientific and clinical investigator for this medication. He took it from pure theory to hypothesis as a Neurovascular Physiologist.... to bench work... to science... to animal trials (I guess he had to work on animals).... to human trials at Joslins Diabetes Center, the premiere Diabetes Research and Treatment Facility in the Nation.... and now its a going to be a prescription.

Dr. Nase, now focus on rosacea please.

Here are some more tidbits:

Purpose

To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.


Study Type:
Interventional
Study Design:
Allocation: Randomized
Control: Placebo Control
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title:
The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM

Resource links provided by NLM:
MedlinePlus related topics: Diabetes
Drug Information available for: Ruboxistaurin

I dont know how many PhD's get to develop clinical medications and have the chance to get published in the most prestigious physician's clinical journal, JAMA (The Journal of the American Medical Association)???? Does this happen... at all?

Let me be the first to congratulate you on your recent accomplishments.... Congrats Geoffrey - JAMA article below... frame that sucker:

JAMA -- Molecular Understanding of Hyperglycemia's Adverse Effects ...

by MJ Sheetz - - Cited by 393 - Related articles
Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during ... inhibitor (Ruboxistaurin mesylate) attenuates leukocyte entrapment in ...
jama.ama-assn.org/cgi/content/full/288/20/2579 - Similar



Looks like Dr. Nase has kept working on this important project until the finally in 2010

Indiana University School of Medicine
Jan 26, 2010 ... Funding: This research has been supported by NIH Grant HL-20605 and Post Doctoral Fellowship Grant and is now in ... Blockade of endothelial PKC with an Eli Lilly Company drug (LY333531) ... Bohlen, H.G. and G.P. Nase. Dependence of Intestinal Arteriolar ...
www.medicine.iu.edu/body.cfm?id=4875 - Cached - Similar


Ruboxistaurin: PKC-β inhibition for complications of diabetes ... by RP Danis - 2009 - Related articles
An inhibitor of the PKC-β isoform ruboxistaurin (RBX) has in vitro and in vivo ...... Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased ...
informahealthcare.com/doi/abs/10.1517/14656560903401620




Protein kinase {beta}II in Zucker obese rats compromises oxygen ... by HG Bohlen - 2004 - Cited by 23 - Related articles
After ruboxistaurin acute administration in obese rats, the PKC blockade ..... [Abstract]; Nase GP, Tuttle J, and Bohlen HG. Reduced perivascular PO2 ...
ajpheart.physiology.org/cgi/content/full/286/2/H492




High concentration of glucose inhibits glomerular endothelial eNOS ... by S Chu - 2004 - Cited by 26 - Related articles
Inhibition of PKC- with 100 nM ruboxistaurin prevented eNOS suppression in ..... Bohlen HG and Nase GP. Dependence of intestinal arteriolar regulation on ...
journal.shouxi.net › ... ›


IT JUST GOES ON>>>>>




Vascular Endothelial Growth Factor and Retinal Diseases by S Dahr - Related articles
inhibition with ruboxistaurin (LY333531) has been shown to ameliorate the ..... Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased ...
www.springerlink.com/index/t207180665687533.pdf




PKCβ inhibitor LY333531

From Axon Ligands™ Collection
Direct Source For All Best!
www.AxonMedChem.com


MERCK

114–120 A PKC inhibitor (ruboxistaurin mesylate) with high affinity for the β1 ..... Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased ...
pt.wkhealth.com/pt/re/merck/selectreference.htm;...
[PDF] Arxaant, INN-ruboxistaurin


File Format: PDF/Adobe Acrobat - Quick View
P-gp substrate) exposure. In vivo. Effect of other active substances on ruboxistaurin. The metabolism of ruboxistaurin is catalyzed principally by CYP3A, ...
www.ema.europa.eu/humandocs/PDFs/EPAR/arxxant/15096407en.pdf

That is quite an accomplishment Geoffrey. It gives me hope that you will continue to collaborate with physicians and researchers to help find that pesky gene behind our disorder.

It just does not seem like anyone is working together. Our one real ray of hope, the National Rosacea Society has failed at their duties and have taken millions of our dollars to advertise for their own product. I truly have never seen anything like this.

I wish you would start your own foundation and let Pascoe keep his $18,000 that he took from us, but I doubt you will take that road again. It's a shame because you have the support.

Is this even a consideration????????????

-Kat

I second that Katie. Either that or rosacea sufferers pull together for once and write a letter to the NRS with legitimate requests. They cannot spend 7 out of every 10 million dollars that we give them on "AWARENESS", because that just gives them a toll free line to their Galderma products. Plus, as Brady pointed out, why are the VP's all making $250,000 from our donations? That's plain crazy. Then we have the 350 physician Brady Barrows foundation and we have a foundation acting like a foundation (the infamous international foundation) which talks about alkaline blood and is solely by Ralph Bass to sell his salt discs. Heck, I'll sell you see salt at half the price.

With everything in perspective above, its no wonder we have not moved an inch. Yet, Dr. Nase developed a prescription drug for Diabetes, collaborated to get us affordable oral ivermectin, and changed laser treatment from single pass to multiple passes... plus he was 10 years ahead of laser physicians with preflushing and post treatment constriction.......

Seth,

You have to remember that it takes many scientists and clinicians to develope a drug. It always works for the best when there is collaboration.

One thing that might be glaringly obvious is that the NRS should ideally be made up of PhD's. The one simple fact is that PhD's are trained to evaluate grants, their objectives and costs. Physicians are not. They are meant to help perform the grants. I think we may be ass backwards here? Any thoughts on this.

This is an excellent protective medication for diabetic nerves and blood vessels.

What we did not expect was to find that it helped to reverse years or decades of damage. Some with severe foot damage who had been wheel chair bound for years slowly started to use crutches... and in some cases, started walking in malls. Of course this took months of treatment, but very exciting... and rewarding.

__________________
_

Best,
Geoffrey

Dr. Geoffrey Nase
Ph.D: Neuro-Vascular Physiologist

Email: drnase1000@hotmail.com
Bibliography: http://drnase.com

All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer.

Excellent!

Is this more for treatment of eye symptoms or neural-vascular symptoms.

- Kat